BioSpace News Archive

Press Releases

Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study

October 30, 2026
·
18 min read
Press Releases

AbbVie Reports Third-Quarter 2026 Financial Results

October 30, 2026
·
31 min read
Press Releases

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

October 30, 2026
·
9 min read
Earnings

‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise

Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range for a takeout.

October 30, 2026
·
3 min read
·
Annalee Armstrong
Neurodegeneration

Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%

Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.

October 30, 2026
·
2 min read
·
Gabrielle Masson
Earnings

Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline

Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings.

October 30, 2026
·
2 min read
·
Nick Paul Taylor
Earnings

Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck

Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s ‘disease agnostic’ pipeline and approach to business development.

October 30, 2026
·
4 min read
·
Heather McKenzie
Earnings

AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals

Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.

October 30, 2026
·
3 min read
·
Gabrielle Masson
Earnings

AstraZeneca employs $1.5B cost savings to reinvest back into growth

“You don’t spend one and a half billion dollars without creating jobs,” AstraZeneca CEO Pascal Soriot said as the pharma announced a new cost savings program alongside third quarter earnings.

October 30, 2026
·
3 min read
·
Annalee Armstrong